Is Provention Bio a Bad News Buy?

Sometimes the market overreacts to a negative development. Shares of Provention Bio (NASDAQ: PRVB) recently plunged after the FDA issued a Complete Response Letter for its diabetes drug teplizumab. In this Motley Fool Live video recorded on July 7, Motley Fool contributors Keith Speights and Brian Orelli discuss whether or not Provention Bio is now a bad news buy.

Continue reading

Source Fool.com